US OptionsDetailed Quotes
SAGE240816P7500
- 0.15
- +0.05+50.00%
15min DelayClose Jul 24 15:49 ET
0.15High0.15Low
0.15Open0.10Pre Close10 Volume164 Open Interest7.50Strike Price150.00Turnover112.10%IV29.19%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier23DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type-0.0963Delta0.0582Gamma69.20Leverage Ratio-0.0106Theta-0.0007Rho-6.66Eff Leverage0.0045Vega
Sage Therapeutics Stock Discussion
Sign in to post a comment
$Sage Therapeutics(SAGE.US$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint
4
$Sage Therapeutics(SAGE.US$ what just happened
$Sage Therapeutics(SAGE.US$ what’s happening
1
$Sage Therapeutics(SAGE.US$ Sage Therapeutics Says Phase 2 SURVEYOR Study Strengthens Cognitive Impact Of Huntington's Disease! For Participants With Hd Got Dalzanemdor or Placebo, Dalzanemdor Was Generally Well-Tolerated With No New Safety Signals Observed
1
Pre-Market Stock Movers
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
24
1
$Apellis Pharmaceuticals(APLS.US$ $Alteryx(AYX.US$ $Barfresh Food(BRFH.US$ $Celanese Corp(CE.US$ $Chegg(CHGG.US$ $Chewy(CHWY.US$ $Extra Space Storage Inc(EXR.US$ $Five9(FIVN.US$ $International Flavors & Fragrances(IFF.US$ $Lucid Group(LCID.US$ $Paramount Global-B(PARA.US$ $Sage Therapeutics(SAGE.US$ $ShockWave Medical(SWAV.US$ $Teradata Corp(TDC.US$ $VistaGen Therapeutics(VTGN.US$ $Wynn Resorts(WYNN.US$
follow for daily watchlist 🚀
follow for daily watchlist 🚀
3
$Sage Therapeutics(SAGE.US$
Great entry point. As long as it is approved and on the market, it will be open for off-label use for MDD if someone really wants it.
Great entry point. As long as it is approved and on the market, it will be open for off-label use for MDD if someone really wants it.
1
$Sage Therapeutics(SAGE.US$ the medicine got approval as a quick fix for PPD 产后抑郁症 after delivery. It can make some big money for that. Sorry but women have many troubles after delivery. Well done.
However MDD 一般抑郁症 is not approved. Although they are not serious enough for MDD. MDD means huge money. And people with MDD typically take pills for years. Guess what, wall street and elites, they know mental health better than you
Now no huge money but just big mon...
However MDD 一般抑郁症 is not approved. Although they are not serious enough for MDD. MDD means huge money. And people with MDD typically take pills for years. Guess what, wall street and elites, they know mental health better than you
Now no huge money but just big mon...
2
No comment yet
TrytosaveabitOP : Sage Therapeutics Inc: Do Not Plan to Conduct Further Clinical Development of Sage-324 in Et
买跌不追涨 : Can't go short
TrytosaveabitOP 买跌不追涨: Sorry. I won’t go short. Don’t believe in it personally! GL
买跌不追涨 TrytosaveabitOP: I also seldom go short